The Santa Cruz, California-based biotechnology company RealSeq Biosciences, Inc., which specializes in RNA-based diagnostics, has increased its Seed funding.
With participation from previous investors, new investors Charleston Angel Partners, Santa Clara Ventures, and Santa Cruz Ventures led the round.
The money will be used by the company to quicken the development of both its liquid biopsy program and its biomarker discovery platform, Ribomarker.
RealSeq Biosciences is a biotechnology company focused on developing RNA technologies for liquid biopsy programs and biomarker discovery. The company is led by CEO Dr. Sergio Barberan-Soler. By analyzing RNA fragments, it has found a way to profile full transcriptomics from liquid biopsies using the Ribomarker platform. With the potential to significantly improve patient outcomes and lower healthcare costs, ribomarkers can offer insights into the course of a disease and the response to treatment.
“With this additional funding, we can accelerate our research and development and get our innovative Ribomarker platform onto the market sooner. We are sure that the field of liquid biopsy and biomarker discovery will be greatly impacted by our transcriptomic analysis technologies, which will ultimately lead to better patient outcomes.”
Sergio Barberan-Soler
Concerning RealSeq
Located in Santa Cruz, California, RealSeq Biosciences, Inc. is a privately held biotech company that specializes in creating cutting-edge technologies for liquid biopsies, single-cell analysis, and biomarker discovery in the fields of infectious diseases and cancer.
The foundational technologies of RealSeq Biosciences, founded in 2019 by Sergio Barberan-Soler, Ph.D., come from his NIH (NHGRI) SBIR-funded research in the fields of single cell analysis and novel small RNA NGS library construction technologies.
RealSeq® NGS services and small RNA sequencing products are distributed both directly and through distribution partnerships throughout the world. Products include RealSeq®-biofluids, which allows small RNA analysis directly from biofluid samples, and RealSeq®-AC, which analyzes small RNA from tissues and cells.
The company’s development pipeline consists of single cell analysis of small RNAs (RealSeq®-SC) and diagnostic platforms for liquid biopsy (RealSeq®-T).
